GlassScriptPhysician profile
Amanda L Morris
NPI 1902999733
$5,887.48
in general payments reported to CMS, 2019-2025
42 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,144 · 2022: $943 · 2023: $635 · 2024: $1,006 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,398.38 | 2021-2025 | |
| Novo Nordisk INC | $826.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $693.15 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $341.68 | 2021-2025 | Entyvio, Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $320.12 | 2021-2025 | |
| Pfizer INC. | $268.90 | 2021-2025 | |
| Lilly USA, LLC | $266.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $133.76 | 2021-2025 | Belsomra, Steglatro, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $128.61 | 2022 | |
| Amgen INC. | $123.32 | 2021-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $107.75 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $106.27 | 2021-2025 | |
| Abbott Laboratories | $95.29 | 2021-2022 | |
| Astellas Pharma US INC | $91.18 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $83.36 | 2021-2023 | Spravato |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.